Biocon’s Board of Directors has approved the unaudited standalone and consolidated financial results for Q2 FY26. The board also greenlit the early full redemption of 50,000 non-convertible debentures and the acquisition of 1,06,86,044 compulsorily convertible debentures of Biocon Biologics Limited. These decisions signify a strategic financial maneuver and continued investment in its subsidiary’s growth prospects. The decisions were made during a board meeting held on November 11, 2025.
Financial Results Approved
Biocon’s Board has officially approved the unaudited financial results, both standalone and consolidated, for the quarter and half-year ended September 30, 2025 (Q2 FY26). These results were prepared in accordance with Indian Accounting Standards (Ind-AS), offering insights into the company’s performance during the specified period.
Early Redemption of Debentures
The Board has authorized the early full redemption of 50,000 unlisted, secured, rated, redeemable Non-Convertible Debentures (NCDs). Each debenture has a face value of ₹1,00,000, totaling ₹500 Crores. These NCDs were originally issued on a private placement basis on May 19, 2023. The redemption is subject to necessary approvals and consents by January 31, 2026.
Acquisition of Convertible Debentures
Biocon will also acquire 1,06,86,044 Unlisted, Secured, Compulsorily Convertible Debentures (CCDs) of Biocon Biologics Limited (BBL), a material subsidiary. These CCDs are being acquired from ESOF III Investment Fund and EAAA India Alternatives Limited, collectively known as “Edelweiss,” and have a face value of ₹10 each. The total acquisition value is ₹300 Crores, expected to be completed by January 30, 2026, subject to approvals.
Commercial Paper Issuance
The Board has approved the issuance of Commercial Papers up to ₹550 Crores through private placement in one or more tranches.
Source: BSE
